Chronic myelogenous leukemia (CML) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome. This arises from a balanced translocation between chromosomes 9 and 22, creating the bcr-abl fusion gene. It is often stated that the only proven curative option is allogeneic stem cell transplantation, which is indicated for only a limited subset of patients. The Bcr-Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy. After imatinib treatment, > 90% of patients had a complete hematologic response, and 70%-80% had a complete cytogenetic response. With 5 years of follow-up, the data are very encouraging and exhibit a major change in the natural history of the disease. The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance. The outlook today for patients with CML is much brighter than that of a few years ago.
Chronic myelogenous leukemia ( CML ) is a progressive and often fatal hematopoietic neoplasm characterized by the presence of the Philadelphia chromosome . This arises from a balanced translocation between chromosomes 9 and 22 , creating the bcr - abl fusion gene . It is often stated that the only proven curative option is allogeneic stem cell transplantation , which is indicated for only a limited subset of patients . The Bcr - Abl tyrosine kinase inhibitor imatinib represented a major advance over conventional CML therapy . After imatinib treatment , > 90 % of patients had a complete hematologic response , and 70%-80 % had a complete cytogenetic response . With 5 years of follow - up , the data are very encouraging and exhibit a major change in the natural history of the disease . The understanding of some of the mechanisms of resistance to imatinib has led to a rapid development of new agents that might overcome this resistance . The outlook today for patients with CML is much brighter than that of a few years ago .
What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?
What tyrosine kinase , involved in a Philadelphia- chromosome positive chronic myelogenous leukemia , is the target of Imatinib ( Gleevec ) ?
BCR-ABL
BCR-ABL